Status:
WITHDRAWN
A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Aspergillosis/Blood
Aspergillosis/Invasive
Eligibility:
All Genders
2+ years
Phase:
PHASE4
Brief Summary
To evaluate the therapeutic effectiveness of voriconazole + micafungin versus voriconazole alone as primary therapy for invasive aspergillosis.
Eligibility Criteria
Inclusion
- Proven, probable or possible invasive aspergillosis
- Patient is 2 years of age or older
Exclusion
- The patient has been administered an antifungal agent (voriconazole, itraconazole, posaconazole, caspofungin, micafungin, anidulafungin, amphotericin B, or lipid formulation of amphotericin B) for \>7 days immediately prior to randomization for treatment of the Possible, Probable, or Proven invasive aspergillosis for which the patient is being enrolled.
- The patient has been treated with voriconazole for \> 7 days immediately prior to randomization
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00423163
Start Date
February 1 2007
Last Update
September 2 2015
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
Fountain Valley, California, United States
3
Los Angeles, California, United States
4
Palo Alto, California, United States